NeuroEPO en ICTUS

1. Zuaznabar MA. Guías de práctica clínica. Enfermedad cerebrovascular. Recomendaciones. 2009. 2. Fernández O. Guía para el manejo de la enfermedad cerebrovascular. 2012. 3. Acccidente cerebrovascular. Disponible en: http://www.nlm.nih.gov/medlineplus/spanish/ency/article/000726.htm. Enciclopedia Médica en Español. 4. Accidente Cerebrovascular: Esperanza en la Investigación. (http://www.ninds.nih.gov/health_and_medical/pubs/accidente_cerebrovascular.htm). 5. WHO. The top ten causes of death. Disponible en: www.who.int/mediacentre/factsheets/fs310/en/index.html 6. Fletcher L SK, Shane M, Sprague B, Scranton R, et al. . Intranasal delivery of erythropoietin plus insulin-like growth factor –I for acute neuroprotection in stroke. . J Neurosurg 2009. ;111(:164-170). 7. Office NA. National Audit Office. Department of Health: progress in improving stroke care. . 2010. 8. MINSAP. AnuarioEstadístico. 2010. 9. WHO. Atlas de las enfermedades cerebrovasculares e ictus de la OMS 2013. 10. Navarro T HD. Aspectos fisiopatológicos de la neuroprotección: en busca del tiempo perdido. . Cuadernos de Neurología 2000 Vol. XXIV. . 11. Arauz A ML, Bonnin E. . Neuroprotección en isquemia cerebral aguda. Estado actual e importancia clínica de la cascada isquémica. . Revista Ecuatoriana de Neurología 2002;11(3. ). 12. Group. TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. . N Engl J Med 1995 333 1581-87. 13. Hacke W DG, Fieschi C, Kaste M, von KR, Broderick JP, et al. . Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. . Lancet 2004;363:768-74. 14. Lees KR BE, von Kummer R, Brott TG, Toni D, Grotta JC, et al. . Time to treatment with intravenous alteplase and outcome in stroke; an updated pooled analysis of ECAA, ATLANTIS;NIND, and EPITHET trials. . Lancet . 2010 375:1695-703. 15. Ehrenreich H HM, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. . Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. . Molecular Medicine 2002 8(8 ):495–505. 16. Enfermedad cerebrovascular. Tratamiento de la enfermedad cerebrovascular oclusiva. Disponible en: http://www.iladiba.com.co/upr/1998/NO21998/HTM/ACV3.asp 17. Mc Arthur K QT, Dawson J, Walters M. . Diagnosis and treatment of transient ischemic attack and ischemic stroke in the acute phase. . BMJ 2011. 18. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004;19(3-4):195-206. 19. Siren AL, Ehrenreich H. Erythropoietin--a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251(4):179-84. 20. Giuseppe R LM. Hematologic Consequences of Renal Failure. Brenner and Rector’s. The Kidney. Sixth Edition 2000:2079-102. 21. Miyake T KC-H, Goldwasser E. . Purification of human erythropoietin. . J BiolChem 1977; 252: 5558-5564.; 252:5558-64. 22. Koury ST BM, Koury MJ. . Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. . Blood 1988 71:524-7. 23. Juul SE SS, Christensen RD. . Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. . Pediatr Res 1999 46: 543- 47. 24. . Bahadur SPK. Physicochemical and physiological considerations for efficient nose-to-brain targeting. . Expert Opin. Drug Deliv. 2012, ;9(1):19-31. 25. Hanson LRF, W.H. . Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. . BMC Neuroscience 2008;9(Suppl 3):S5. 26. Brines ML GP, Keenan S, Agnello D, deLanerolle NC, Cerami C et al. . From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. . ProcNatlAcadSci USA 2000;19 10526-31. 27. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004;10(2):93-8. 28. Bartesaghi S, Marinovich M, Corsini E, Galli CL, Viviani B. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005;26(5):923-8. 29. Masuda S NM, Takahata K, et al. . Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. . J BiolChem 1993; 268:11208–16. 30. Marti HH GM, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, et al. . Detection of erythropoietin in human cerebrospinal fluid: intrinsic erythropoietin production in the brain. . Kidney Int 1997 51:416-18. 31. Sosa I, Cuz, J., et al Paso de la molécula de eritrpopoyetina humana recombinante con bajo contenido de acido sialico al Sistema nervioso central por la vía intranasal en los modelos del meriones unguicularus y el primate no humano Macaca fascicularis. . Rev. Salud. Anim. 2007;29(2):1-6. 32. Nuñez Y, Bueno, P.V., Carrillo, D.C., et al. . Neuroprotective effect of a nasal formulation of erythropoietin with low salicaci content. . Rev. Cubana Farm. 2009 43(1):1-13. 33. Sosa I, García Rodríguez J.C., Santana, J., et al Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. . Pharmacology Online 2006;1:100-12. 34. Gao Y, et al. . Different expression patterns of Ngb and EPOR in the cerebral cortex and Hyppocampus revealed distintic therapeutic effects of intranasal delivery of NeuroEPO for ischemic insults to the Gerbil brain. . J Histochem and cytochem 2011 59: 214-28. 35. Rodríguez YM, Y.; Muñoz, A.; Subirós, N.; González-Quevedo, A.; Sosa, I.; García, J.C. . Treatment with Nasal Neuro-EPO Improves the Neurological, Cognitive, and Histological State in a Gerbil Model of Focal Ischemia. . The Scientific World JOURNAL 2010;10:2288–300. 36. Sosa Iea. Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model In the Mongolian Gerbil. . The scientific World Journal. 2012;Vol 2012 article ID 607498, . 37. CENPALAB. Evaluación del efecto de la aplicación intranasal de NeuroEPO sobre el número de reticulocitos en el modelo normocitémico de ratón B6D2F1.Informe final 2008. 38. Lagarto A, Bueno V, Guerra I, Valdes O, Couret M, Lopez R, et al. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp Toxicol Pathol 2011;63(6):563-7. 39. CIDEM. Evaluación de la irritación nasal de una formulación de eritropoyetina humana recombinante con bajo contiendo de ácido siálico. Informe final 2012. 40. CIDEM. Informe de inmunogenicidad a nivel sistémico de una formulación nasal de eritropoyetina humana recombinante con bajo contenido de ácido síalico. Informe final. 2012. 41. CIM. Evaluación de la seguridad de la administración nasal de NeuroEPO en voluntarios sanos. Informe Final. . 2013. 42. FDA. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy individuals. 2005. 43. CENPALAB. Estudio del efecto de la aplicación intranasal de NeuroEPO sobre algunos parámetros hematológicos y evaluación de efectos adversos en los modelos de la rata SpragueDawley, la especie de primate no humano Macaca Fascicularis, y el modelo de isquemia unilateral permanente en el Gerbo de Mongolia. Informe Final. Febrero. 2012. 44. Shyeilla V, Hanson L, Frey W. Intranasal delivery to the Central Nervous System: Mechanism and Experimental Considerations. J Pharm Scie 2010:1654-73. 45. Ehrenreich HM, Dembowski C, Cepek L, Lewczuk P, Stiefel M. Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine 2002 8(495–505). 46. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:647-56. 47. Gao Y. Different expression patterns of ngb and epor in the cerebral cortex and hyppocampus revealed distintic therapeutic effects of intranasal delivery of neuroepo for ischemic insults to the gerbil brain. J . Histochem and cytochem 2011 59:214-28. 48. Lagarto A, Bueno V, Sanchez JA, Couret M, Valdes O, Barzaga P, et al. Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects. Curr Neurovasc Res 2012;9(4):233-8. 49. Gene S, Koroglu TF, Gene K. Erythropoietin and the nervous system Brain Res 1000:19-31. . 50. Garcia-Rodriguez JC, Sosa-Teste I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. ScientificWorldJournal 2009;9:970-81. 51. Common Terminology Criteria for adverse events v3.0 (CTCAE). 2006. 52. CECMED. Regulación 21-08. Requisitos para la autorización y modificación de ensayos clínicos. 2008. 53. W.H.O. The causality assessment of suspected adverse reactions 2006. 54. CECMED. Regulación No. 45/2007 Requerimientos para la Notificación y el Reporte de Eventos Adversos Graves e Inesperados en los Ensayos Clínicos. 2007. 55. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35-41. 56. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable subtypes of cerebral infarction. The Lancet 1991;337(8756):1521-26.